These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22277895)

  • 21. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
    Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Int J Cardiol; 2012 Oct; 160(2):109-13. PubMed ID: 21546102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Panzer S; Sunder-Plassmann R; Mannhalter C; Steiner S
    Int J Cardiol; 2013 Jun; 166(1):126-31. PubMed ID: 22075408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
    Phankingthongkum R; Panchavinnin P; Chinthammitr Y; Tresukosol D; Chotinaiwattarakul C; Tungsubutra W; Wongpraparut N; Kitrattana B; Leewanun P
    J Med Assoc Thai; 2013 May; 96(5):538-43. PubMed ID: 23745307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
    Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
    Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?
    Pendyala LK; Loh JP; Lhermusier T; Minha S; Magalhaes MA; Torguson R; Chen F; Satler LF; Pichard AD; Waksman R
    Am Heart J; 2014 Oct; 168(4):545-51. PubMed ID: 25262265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
    Schulz S; Sibbing D; Braun S; Morath T; Mehilli J; Massberg S; Byrne RA; Schömig A; Kastrati A
    Am Heart J; 2010 Aug; 160(2):355-61. PubMed ID: 20691843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
    Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
    Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
    Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
    J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
    Leng WX; Ren JW; Cao J; Cong YL; Cui H; Hu GL; Hu QQ; Niu H; Fan L
    Thromb Res; 2013 Mar; 131(3):218-24. PubMed ID: 23340097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Am J Cardiol; 2009 Nov; 104(9):1189-93. PubMed ID: 19840560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
    Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
    J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.